Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial

Cue Biopharma said Sunday its chronic hives candidate cleared a mid-stage trial, marking its first clinical data since its strategic pivot from cancer into immunology. In a Phase 2 China study in chronic spontaneous urticaria ...